# SS-31 MMPOWER: 6-minute walk in mitochondrial myopathy

Source: https://pepvault.app/research/ss-31-mmpower-2018

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [SS-31](https://pepvault.app/research#ss-31)

Randomized trial · people

# SS-31: walk distance rose with dose in 5-day MMPOWER trial

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

An early, short trial in adults with primary mitochondrial myopathy found walking distance improved with higher intravenous doses of elamipretide, without added safety concerns over 5 days. Larger, longer trials are still needed.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 36
- **Published:** 2018
- **Journal:** Neurology

## What they tested

The team tested whether elamipretide (SS-31) is safe and improves exercise ability in adults with primary mitochondrial myopathy, a muscle disease confirmed by genetic testing in this trial.

## How the study was done

A phase I/II, multicenter, randomized, double-blind, placebo-controlled trial in 36 adults with genetically confirmed primary mitochondrial myopathy. Participants got elamipretide into a vein at 0.01, 0.1 or 0.25 mg/kg/h, or placebo (a dummy infusion), for 2 hours in a dose-escalating order. The main measure was the 6-minute walk test (how far a person walks in 6 minutes) after 5 days.

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

People in the highest-dose arm walked an average of 64.5 m farther at day 5, compared with 20.4 m farther in the placebo group (p = 0.053). Walk distance rose with dose across the elamipretide arms (p = 0.014). After adjusting for other factors that could affect results, the change was 51.2 m for the highest dose vs 3.0 m for placebo (p = 0.0297). No significant differences showed up in the other efficacy measures or in safety.

## What it doesn’t show

This was a small trial with only 5 days of treatment, so it can't show longer-term benefit or safety. Elamipretide was given into a vein, and the other measures, such as exercise testing, symptoms and blood and urine markers, showed no significant change.

## The paper

Karaa et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018.

- [PubMed (PMID 29500292)](https://pubmed.ncbi.nlm.nih.gov/29500292/)
- [The paper (DOI 10.1212/WNL.0000000000005255)](https://doi.org/10.1212/WNL.0000000000005255)

## The compound

- [SS-31: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021)
- [All 12 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on SS-31

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024) Randomized trial · people · 2024
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023) Randomized trial · people · 2023
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021) Randomized trial · people · 2021
- [SS-31 raised muscle ATP capacity after one dose in older adults](https://pepvault.app/research/ss-31-roshanravan-2021) Randomized trial · people · 2021
- [SS-31: less kidney hypoxia after renal artery stenting in pilot](https://pepvault.app/research/ss-31-saad-2017) Randomized trial · people · 2017
- [SS-31 did not significantly cut infarct size in EMBRACE STEMI](https://pepvault.app/research/ss-31-embrace-stemi-2016) Randomized trial · people · 2016
- [Every study on SS-31](https://pepvault.app/research#ss-31)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021)
- [All 12 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on SS-31](https://pepvault.app/research#ss-31)

## The library

- [SS-31](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
